Patents

US 12767635 B2: Lipoxygenase inhibitors

Granted
2026-10-20
Filed
2021-03-25 application 17906885
Type
Utility · 7 claims
Elsewhere
Google Patents ↗ · USPTO patent document ↗ · USPTO Patent Center record ↗

Abstract

Various embodiments of the present disclosure are directed to compounds having Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), and/or pharmaceutically acceptable salts thereof. The compounds can be suitable for inhibiting lipoxygenases, and/or treating associated diseases, such as Alzheimer's disease. In some embodiments, the compounds may be administered to a patient as part of a pharmaceutical formulation.

Source: PTBLXML, file of 2026-10-20 (ipgb20261020.xml).

Assignees

AssigneeTypePlaceAlso on furp.orgSource
SRI International 676 patentsUS company or organizationMenlo Park, CASRI INTERNATIONAL Federal lobbying client EXACT high confidence: identical full name and state
SRI INTERNATIONAL Nonprofit EXACT high confidence: identical full name and state
PTBLXML, file of 2026-10-20

Inventors

InventorPlacePatentsPerson pageSource
Ling JongSunnyvale, CA8PTBLXML, file of 2026-10-20
Raymond NgPleasant Hill, CAPTBLXML, file of 2026-10-20
Nathan CollinsSan Mateo, CA19PTBLXML, file of 2026-10-20

CPC categories

SubclassCategoryFirst groupSource
C07DHeterocyclic compoundsC07D209/88PTBLXML, file of 2026-10-20

Cooperative Patent Classification, as currently assigned (one row per subclass).

Assignments and security interests

No recorded assignments or security interests on file for this patent.

USPTO bulk data: PatentsView granted patents, disambiguated (PVGPATDIS) for patents, assignees, inventors, places and CPC categories; the USPTO Patent Assignment Dataset (ECORSEXC) for assignments and security interests. Patents filed in the last 20 years. No claims or full text. Links to other records are by name (and state): EXACT means the identical full name and state; FUZZY means a looser name match, with the confidence shown.